Company Overview
Pyxis Oncology, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it engages in the clinical stage development of therapeutics designed to treat solid tumors. The company's primary asset is its lead antibody-drug conjugate (ADC) product candidate, PYX-201, an investigational novel ADC constructed from human immunoglobulin G1 (IgG1) that is currently undergoing Phase 1 clinical trials. In terms of scale, the company holds a market capitalization of $82.31M and reported trailing twelve-month revenue of $13.86M, while its employee count is listed as N/A. These financial figures indicate that Pyxis Oncology functions as a mid-sized biotechnology entity with a relatively modest revenue base compared to large-cap pharmaceutical firms, reflecting its position as a company still in the early phases of product development and commercialization where significant capital is typically required to advance clinical programs toward approval.
Financial Health
The company reported revenue of $13.86M for the trailing twelve months, yet this revenue generated a net income of $-79,621,000 and an EBITDA of $-77,334,000, revealing a substantial gap between top-line generation and profitability that points to a cost structure dominated by research and development expenses rather than operational overhead. Free cash flow stood at $-31,380,124, indicating that the company is currently burning cash to fund its operations and clinical trials, which limits immediate financial flexibility but is a common characteristic for clinical-stage biotechs. The gross margin is 82.8%, suggesting high efficiency in the production of its therapeutic candidates, while the operating margin is -159.5% and the profit margin is 0.0%, highlighting that the company is not yet covering its operating costs with its current revenue stream. On the balance sheet, the company holds $66.86M in cash against $18.67M in debt, resulting in a debt-to-equity ratio of 34.96, which suggests a conservative capital structure given the significant cash reserves relative to outstanding obligations. The current ratio is 3.41, indicating a strong ability to meet short-term obligations with its current assets, providing a buffer against liquidity risks. Return on equity is -91.4% and return on assets is -41.1%, metrics that reveal management is currently deploying capital to generate losses rather than profits, a typical scenario for companies prioritizing asset growth and clinical progress over immediate shareholder returns.
Valuation Assessment
The trailing P/E ratio is N/A due to the company's lack of net income, while the forward P/E is -1.01, implying that the market expects earnings to remain negative in the near term as the company continues to invest in its clinical pipeline. The price-to-book ratio is 1.54, indicating that the market values the company at a 54% premium over its book value, which may reflect expectations of future asset appreciation or successful clinical trial outcomes. Alternative valuation metrics show a price-to-sales ratio of 5.94 and an EV/EBITDA of -0.44, suggesting the market is pricing the stock based on its revenue potential and intangible assets rather than current earnings power. The 52-week high is $5.55 and the 52-week low is $0.83, meaning the stock has experienced significant volatility and currently trades well within this wide historical range. The beta value is 1.46, which indicates that the stock's price volatility is 46% higher than the broader market, exposing investors to greater price swings in response to market movements or specific biotechnology sector developments.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, as the company has not yet achieved consistent profitability or a long enough history of positive growth to calculate these specific annualized rates. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are reinvested back into the business to fund clinical trials and operational expansion rather than being distributed to shareholders. The absence of a dividend program is consistent with the lifecycle of a clinical-stage biotechnology firm that requires substantial capital retention to advance its lead product, PYX-201, through the regulatory approval process. Overall, the growth and income profile is defined by high cash burn and zero current income, focusing entirely on long-term potential rather than short-term financial returns or shareholder distributions.